By Lori L. Alexander, MTPW, ELS, MWC Posted: December 2017 Since 2006, the Bonnie J. Addario Lung Cancer Foundation (ALCF) has brought together a diverse group of physicians, organizations, industry […] Read more
By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis […] Read more
Posted: June 2017 By Νiki Karachaliou, MD, PhD The identification of oncogenic driver alterations in non-small cell lung cancer (NSCLC), such as EGFR mutations and ALK rearrangements, each of which […] Read more
Posted: April 2017 Opinion-No: Emily Stone, MBBS, MMed There is little doubt that lung cancer patients and the people around them who smoke need to stop. Smoking cessation can improve […] Read more
Lung Cancer in Never-Smokers: An Epidemiologic Perspective
Daniel S.W. Tan, MD, PhD+more
Posted: February 2017 By Chee-Keong Toh, MD, and Daniel SW Tan, MD The recent decade has seen much interest in lung cancer in never-smokers (LCNS), in most part attributed to […] Read more
Memoir Resonates with Oncologists and Patients with Lung Cancer
By Lori Alexander, MTPW, ELS, MWC How does a person with stage IV lung cancer live a meaningful life? That’s the question Paul Kalanithi explores in When Breath Becomes Air, […] Read more
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
Erin JungmeyerIn light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
In an interview with ILCN, Drs. Puneeth Iyengar and Matthias Guckenberger said despite a lack of phase III data in this space, science-based recommendations are needed to optimize multimodal therapy. Read more
Demystifying AI: Current Insights on Artificial Intelligence in Thoracic Oncology
Raymond H. Mak, MD+more
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field. Read more
Thoracic Oncologists Divided Regarding Role of Neoadjuvant Chemoimmunotherapy
Erin JungmeyerConsensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC. Read more